JOUD HAJJAR to Neoplasms
This is a "connection" page, showing publications JOUD HAJJAR has written about Neoplasms.
Connection Strength
2.012
-
Associations between the gut microbiome and fatigue in cancer patients. Sci Rep. 2021 03 12; 11(1):5847.
Score: 0.259
-
Immune System in Action. Adv Exp Med Biol. 2021; 1342:1-43.
Score: 0.256
-
T-cell agonists in cancer immunotherapy. J Immunother Cancer. 2020 10; 8(2).
Score: 0.251
-
Overview of Basic Immunology and Clinical Application. Adv Exp Med Biol. 2020; 1244:1-36.
Score: 0.238
-
Biomarkers of response to immune checkpoint blockade in cancer treatment. Crit Rev Oncol Hematol. 2018 Oct; 130:108-120.
Score: 0.216
-
Overview of Basic Immunology and Translational Relevance for Clinical Investigators. Adv Exp Med Biol. 2018; 995:1-41.
Score: 0.208
-
Overview of Basic Immunology for Clinical Investigators. Adv Exp Med Biol. 2017; 995:1-31.
Score: 0.194
-
Metformin: an old drug with new potential. Expert Opin Investig Drugs. 2013 Dec; 22(12):1511-7.
Score: 0.154
-
Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer. 2021 04; 9(4).
Score: 0.065
-
Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors. J Immunother Cancer. 2020 04; 8(1).
Score: 0.061
-
Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1).
Score: 0.060
-
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs. 2018 08; 36(4):638-646.
Score: 0.051